Therapeutic drug monitoring of infliximab in spondyloarthritis. A review of the literature

Available evidence indicates that a therapeutic drug monitoring strategy leads to major cost savings related to the anti‐tumour necrosis factor‐α therapy in both inflammatory bowel disease and rheumatoid arthritis (RA) patients, with no negative impact on efficacy. However, although the systematic u...

Ausführliche Beschreibung